Elion Therapeutics

About Elion Therapeutics

Elion Therapeutics, formerly known as Sfunga Therapeutics, is a clinical-stage biotechnology company concentrating on the development of treatments for life-threatening invasive fungal infections (IFIs). The company was co-founded by Dr. Kieren Marr, an international expert in fungal diseases who serves as the company's President and Chief Executive Officer. Dr. Marr's extensive background includes serving as the Director of Transplant and Oncology Infectious Diseases at Johns Hopkins University School of Medicine until 2022, a role that directly informs the company's mission. The company's name is inspired by Nobel Prize winner Gertrude B. Elion, a pioneer in rational drug design. Established to address the growing concern over IFIs, which have become more prevalent due to factors like increased use of biologic immunosuppression and environmental changes, Elion operates in the antifungal therapeutics market. The company is focused on patients with compromised immune systems, such as those undergoing cancer treatment, organ transplant recipients, and individuals with severe pulmonary disease, who are at high risk for these infections.

The company's business model is centered on the research and development of novel pharmaceutical assets. Its financial strategy relies on venture capital funding to advance its drug candidates through the rigorous and costly clinical trial and regulatory approval process. In a significant milestone, Elion secured $81 million in a Series B financing round in June 2024, co-led by Deerfield Management and the AMR Action Fund, with participation from Illinois Ventures. This capital is earmarked for advancing the company's lead product candidate, SF001 (also referred to as EL219). The company's core strategy is based on the principle of using mechanistic insights to create optimized versions of natural products.

Elion's primary asset, SF001, is a next-generation polyene antifungal administered via IV infusion. It is a novel analog of amphotericin B (AmB), a potent antifungal agent used since the 1950s that is known for causing significant kidney toxicity in up to 80% of patients. SF001 has been rationally designed to mitigate this renal toxicity by having a higher specificity for fungal cells over human cells, thereby maintaining efficacy while improving the safety profile. The drug has completed a first-in-human single-ascending dose study and is currently in a multiple-ascending dose study. In 2023, the U.S. Food and Drug Administration (FDA) granted SF001 both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the early treatment of presumed invasive fungal disease and for treating invasive aspergillosis, signaling a recognition of its potential to address a critical unmet medical need. An oral formulation is also reported to be in the feasibility phase.